| Title |
Current research for a vaccine against Lassa hemorrhagic fever virus
|
|---|---|
| Published in |
Drug Design, Development and Therapy, August 2018
|
| DOI | 10.2147/dddt.s147276 |
| Pubmed ID | |
| Authors |
Bryce M Warner, David Safronetz, Derek R Stein |
| Abstract |
Lassa virus (LASV) is a rodent-borne arenavirus endemic to several West African countries that causes Lassa fever (LF). LF is typically mild but it can cause severe disease characterized by hemorrhagic fever and multi-organ failure. A current outbreak of LASV in Nigeria has seen greater than 300 cases with a case fatality rate of 22%. Currently, there are limited treatment options and no vaccine candidates are approved to prevent LASV infection. The Coalition for Epidemic Preparedness Innovations has identified LASV as an emerging pathogen of high consequence and this has resulted in a push for several preclinical vaccine candidates to be advanced toward clinical trials. Here, we discuss several important aspects of LASV infection including immunobiology, immune evasion, and correlates of protection against LF, which have been identified through animal models and human infections. In addition, we discuss several vaccine candidates that have shown efficacy in animal models that could be advanced toward clinical trials. The increased fatality rate seen in the recent LASV outbreak in Nigeria highlights the importance of developing effective treatment and prevention strategies against LF. The spike in LASV cases seen in West Africa has the potential for increased mortality and human-to-human transmission, making the development and testing of effective vaccines for LASV critical. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 50% |
| Germany | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 164 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 164 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 27 | 16% |
| Researcher | 26 | 16% |
| Student > Bachelor | 15 | 9% |
| Student > Ph. D. Student | 14 | 9% |
| Student > Postgraduate | 10 | 6% |
| Other | 22 | 13% |
| Unknown | 50 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 16% |
| Immunology and Microbiology | 17 | 10% |
| Biochemistry, Genetics and Molecular Biology | 16 | 10% |
| Agricultural and Biological Sciences | 13 | 8% |
| Nursing and Health Professions | 10 | 6% |
| Other | 28 | 17% |
| Unknown | 54 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2022.
All research outputs
#16,053,755
of 25,385,509 outputs
Outputs from Drug Design, Development and Therapy
#925
of 2,268 outputs
Outputs of similar age
#196,886
of 341,886 outputs
Outputs of similar age from Drug Design, Development and Therapy
#32
of 69 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,886 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.